Skip to main content
Psych Congress  

Short- and Long-term Treatment with Lurasidone or Quetiapine XR in Patients With Schizophrenia: Effect on Metabolic Syndrome

Peter Werner, PhD. Jonathan Meyer, MD. Josephine Cucchiaro, PhD. Robert Silva, PhD. Andrei Pikalov, MD, PhD. Jay Hsu, PhD. Fred Grossman, DO. Antony Loebel, MD.
Sunovion Pharmaceuticals Inc.

Objectives: To evaluate the effect of short- and long-term treatment with lurasidone and quetiapine XR (QXR) on the prevalence of metabolic syndrome (MetS).
Methods: The effects of fixed doses of lurasidone (80 mg/d; 160 mg/d), QXR (600 mg/d), and placebo on the prevalence of MetS were evaluated in subjects with schizophrenia enrolled in a double-blind, placebo-controlled 6 week study, and a subsequent 12 month, double-blind, flexible-dose continuation study with lurasidone (40-160 mg/d) and QXR (200-800 mg/d). The analysis utilized National Cholesterol Education Program (NCEP) criteria for MetS.
Results: At baseline, the prevalence of MetS was similar for lurasidone (9.8%), QXR (10.9%) and placebo (11.6%). After 6 weeks of treatment, the prevalence of MetS was lower in patients receiving lurasidone or placebo (12.3% and 12.8%) compared with QXR (21.7%; p<0.05 for lurasidone vs. QXR). For the subgroup with MetS at baseline, the following median changes were observed at Week 6-LOCF for weight: lurasidone, +0.2; QXR, +1.3; placebo, +0.3 kg; triglycerides: lurasidone, -40.0; QXR, -3.0; placebo, -62.0 mg/dL; and glucose: lurasidone, +0.0; QXR, +10.5; placebo, +1.0 mg/dL. Among patients completing 12 months of treatment, the proportion meeting NCEP criteria for MetS was significantly lower for lurasidone vs. QXR (2.6% vs. 12.1%; p=0.046). 
Conclusions: Treatment with lurasidone was associated with significantly lower rates of MetS when compared with quetiapine XR at both 6 weeks and 12 months. In patients with MetS at baseline, 6 weeks of treatment with lurasidone was associated with improvement in lipid parameters, and minimal change in weight.  

Back to Top